---
layout: ../../layouts/Article.astro
title: "BPC-157: A Complete Evidence-Based Guide"
description: "A science-backed guide to BPC-157 (Body Protection Compound-157) covering mechanisms of action, research-backed benefits, dosage protocols, reconstitution, side effects, and legal status."
image: /images/articles/bpc-157.webp
date: 2026-02-13
category: "Peptide Guides"
tags: ["BPC-157", "body protection compound", "peptides", "gut healing", "tendon repair", "neuroprotection", "research peptides"]
author: "PeptideRundown Team"
---

# BPC-157: A Complete Evidence-Based Guide

BPC-157 is one of the most widely discussed peptides in the research and biohacking communities, and for good reason. With over two decades of published preclinical research suggesting benefits ranging from gut healing to tendon repair, it has attracted significant interest from athletes, clinicians, and researchers alike.

> **Key Takeaways**
> - BPC-157 is a 15-amino-acid synthetic peptide derived from a protein in human gastric juice
> - Preclinical research shows benefits for gut healing, tendon repair, neuroprotection, and more
> - It works through angiogenesis, nitric oxide modulation, and growth factor upregulation
> - No large-scale human clinical trials exist as of early 2026
> - The FDA has restricted compounding pharmacy access in the US
> - Common dosing is 250-500 mcg once or twice daily via subcutaneous injection

But what does the science actually say? In this guide, we break down everything the current evidence tells us about BPC-157: what it is, how it works, what it may do, and what we still don't know.

## What Is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a chain of 15 amino acids, derived from a protein found in human gastric juice. Its amino acid sequence is:

**Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val**

The "body protection compound" designation comes from its parent protein, which is naturally present in the stomach and appears to play a role in maintaining the integrity of the gastrointestinal lining. BPC-157 is a partial sequence of this larger protein, isolated and studied for its concentrated biological activity.

Unlike many peptides that degrade rapidly in gastric acid, BPC-157 is notable for its stability in the gastrointestinal tract. This property has made it a candidate for both injectable and oral administration in research settings.

The peptide was first characterized by researchers at the University of Zagreb in Croatia, led by Professor Predrag Sikirić, whose laboratory has published the majority of the existing literature on BPC-157 since the early 1990s [1].

### Key Facts at a Glance

- **Type:** Synthetic pentadecapeptide (15 amino acids)
- **Molecular Weight:** ~1,419 Da
- **Origin:** Partial sequence of human gastric juice protein BPC
- **Primary Research:** Preclinical (animal models, in vitro)
- **Human Trials:** Limited; no completed large-scale randomized controlled trials as of early 2026
- **FDA Status:** Not approved for human use


## How BPC-157 Works: Mechanisms of Action

BPC-157's mechanisms are complex and not fully elucidated, but research has identified several key pathways through which it appears to exert its effects.

### 1. Angiogenesis and Blood Vessel Formation

One of BPC-157's most well-documented effects is the promotion of angiogenesis, the formation of new blood vessels. Studies show it upregulates vascular endothelial growth factor (VEGF) expression and promotes the VEGF-VEGFR2 signaling pathway, which is critical for tissue repair and wound healing [2, 3].

This angiogenic effect is believed to be a central mechanism behind BPC-157's observed benefits in tendon, ligament, muscle, and gut tissue healing.

### 2. Nitric Oxide (NO) System Modulation

BPC-157 interacts with the nitric oxide system in a nuanced way. Research suggests it can counteract both NO excess and NO deficiency, acting as a modulator rather than a simple agonist or antagonist [4]. This is significant because dysregulated NO signaling is implicated in a range of conditions, from gastrointestinal ulcers to cardiovascular dysfunction.

### 3. Growth Factor Upregulation

Beyond VEGF, BPC-157 has been shown to influence several growth factors relevant to tissue repair, including:

- **EGF (Epidermal Growth Factor)**, involved in mucosal healing
- **HGF (Hepatocyte Growth Factor)**, relevant to liver and tissue repair
- **FGF (Fibroblast Growth Factor)**, critical for connective tissue

This broad growth factor engagement may explain why BPC-157 appears to accelerate healing across multiple tissue types [5].

### 4. FAK-Paxillin Pathway

Research has demonstrated that BPC-157 activates the FAK-paxillin signaling pathway, which plays a key role in cell migration, adhesion, and tissue remodeling. These are essential processes in wound healing and tendon repair [6].

### 5. Dopaminergic System Interaction

BPC-157 appears to interact with the dopaminergic system, showing protective effects against dopamine-related neurotoxicity in animal models. Studies have shown it can counteract the effects of both dopamine agonists and antagonists, suggesting a stabilizing or modulatory role [7].

### 6. GABAergic System

There is evidence that BPC-157 interacts with the GABA system, which may contribute to reported anxiolytic-like effects in animal models [8].


## What BPC-157 Can Do: Research-Backed Benefits

> **Important:** The vast majority of BPC-157 research is preclinical, conducted in rodent models or in vitro (cell cultures). While the body of evidence is substantial and consistent, human clinical data remains very limited. The benefits described below reflect findings from animal studies and should not be assumed to translate directly to humans.

### Gastrointestinal Healing

As a compound derived from gastric juice, it is perhaps unsurprising that BPC-157's strongest evidence base involves the GI tract.

BPC-157 has shown protective and healing effects across multiple GI conditions in animal studies:

- **Ulcer healing** — accelerated healing of gastric, duodenal, and colonic ulcers caused by NSAIDs, alcohol, stress, and surgery [1, 9]
- **IBD models** — reduced inflammation, promoted mucosal healing, and improved clinical scores comparable to standard treatments [10]
- **Anastomosis healing** — accelerated surgical gut healing and reduced adhesion formation [11]
- **Esophageal damage** — protective effects against acid reflux-induced lesions [9]

### Tendon and Ligament Repair

The tendon-healing effects of BPC-157 have generated some of the most interest in the athletic and sports medicine communities.

**Achilles tendon:** In a widely cited study, BPC-157 significantly accelerated the healing of transected Achilles tendons in rats, with improved biomechanical properties and more organized collagen fiber formation compared to controls [12].

**Medial collateral ligament (MCL):** Similar acceleration of healing has been demonstrated in MCL injury models [13].

**Mechanism:** The tendon-healing effects appear mediated through increased collagen production, tendon fibroblast proliferation, activation of the FAK-paxillin pathway, and enhanced angiogenesis at the injury site [6, 12].

### Muscle Healing

BPC-157 has shown positive effects on muscle healing in several injury models:

- Accelerated recovery from crush injuries
- Improved healing of surgically transected muscles
- Protective effects against muscle wasting associated with systemic conditions [14]

### Bone Healing

Limited but promising research suggests BPC-157 may accelerate fracture healing. Studies in rabbit models showed improved bone callus formation and faster radiographic healing when BPC-157 was administered following segmental bone defects [15].

### Neuroprotection

BPC-157 has demonstrated several neuroprotective properties in animal models:

**Traumatic brain injury (TBI):** In rat TBI models, BPC-157 administration reduced brain edema, improved behavioral outcomes, and promoted neuronal survival [16].

**Peripheral nerve injury:** Studies have shown accelerated nerve regeneration and improved functional recovery following sciatic nerve crush injuries [17].

**Dopaminergic protection:** BPC-157 appears to counteract neurotoxic effects in models relevant to Parkinson's-like pathology, including those induced by MPTP and cuprizone [7].

**Serotonin system:** Evidence suggests BPC-157 modulates the serotonergic system and may exert antidepressant-like effects in animal behavioral models [8].

### Cardiovascular Effects

**Blood pressure regulation:** BPC-157 has shown the ability to counteract both hypertensive and hypotensive states in animal models, suggesting a modulatory rather than unidirectional effect [4].

**Arrhythmia:** Some studies have demonstrated anti-arrhythmic properties, with BPC-157 counteracting digitalis-induced arrhythmias and other models of cardiac rhythm disturbance [18].

**Vascular protection:** Through its effects on the NO system and angiogenesis, BPC-157 appears to promote healthy vascular function and endothelial integrity.

### Liver Protection

BPC-157 has shown hepatoprotective effects in several models of liver damage, including alcohol-induced liver injury and NSAID-induced liver toxicity. It appears to promote liver regeneration and reduce inflammatory markers [19].

### Cytoprotection Against NSAID Damage

One of BPC-157's most consistently demonstrated effects is protection against the damaging effects of NSAIDs (non-steroidal anti-inflammatory drugs). This includes protection of the gastric mucosa, intestinal lining, liver, and brain from NSAID-induced damage [1, 9].


## BPC-157 Dosage: How Much to Take

> **Quick Summary:** Most protocols use **250–500 mcg** once or twice daily via subcutaneous injection, typically for **4–8 weeks**.

### Commonly Referenced Dosage Ranges

Most discussions of BPC-157 dosing in the research and clinical communities reference the following ranges:

| Parameter | Range |
|-----------|-------|
| **Typical dose** | 200–500 mcg per administration |
| **Frequency** | 1–2 times daily |
| **Duration** | Typically 4–8 weeks in reported protocols |
| **Body-weight equivalent** | ~2.5–10 mcg/kg (extrapolated from rodent studies) |

The most commonly discussed human-equivalent dose, extrapolated from the animal literature using allometric scaling, falls in the range of **250–500 mcg once or twice daily**.

### Routes of Administration

**Subcutaneous injection** is the most commonly discussed route for systemic effects or localized tissue repair. Injections are typically administered near the site of injury when targeting a specific area (e.g., near an injured tendon or joint).

**Oral administration** is discussed primarily for gastrointestinal applications. BPC-157 is notable for its stability in gastric acid, which is unusual among peptides and makes oral administration a viable research route. In animal studies, both oral and injectable routes have demonstrated efficacy, though the optimal route may depend on the target tissue [1].

**Intramuscular** and **intraperitoneal** routes have been used in animal research but are less commonly discussed in human contexts.

### Cycling

There is no established evidence-based cycling protocol. Some practitioners in the clinical community have discussed protocols of 4–6 weeks on, followed by a break, but this is based on clinical judgment rather than controlled trial data.


## How to Reconstitute BPC-157 (Step-by-Step)

BPC-157 is typically supplied as a lyophilized (freeze-dried) powder in a sealed vial. It must be reconstituted with a sterile solvent before use. The most common solvent is **bacteriostatic water** (sterile water containing 0.9% benzyl alcohol as a preservative).

### Step-by-Step Reconstitution

1. **Gather materials:** BPC-157 vial (lyophilized powder), bacteriostatic water, insulin syringe (typically 1 mL / 100 unit), alcohol swabs.

2. **Clean the vial tops** of both the BPC-157 vial and the bacteriostatic water vial with alcohol swabs. Allow to dry.

3. **Draw bacteriostatic water** into the syringe. The amount depends on your desired concentration. A common approach:
   - **5 mg vial + 2 mL bacteriostatic water = 2,500 mcg/mL** (each 0.1 mL / 10 units on an insulin syringe = 250 mcg)
   - **5 mg vial + 1 mL bacteriostatic water = 5,000 mcg/mL** (each 0.1 mL = 500 mcg)

4. **Inject the water slowly** into the BPC-157 vial, aiming the stream against the glass wall, not directly onto the powder. This prevents damage to the peptide.

5. **Swirl gently** until fully dissolved. Do not shake vigorously.

6. **Store the reconstituted solution** in the refrigerator (2-8°C / 36-46°F). Do not freeze once reconstituted.

For a more detailed walkthrough with dosage calculations, see our [complete peptide reconstitution guide](/articles/how-to-reconstitute-peptides).

### Storage and Stability

- **Lyophilized (unreconstituted):** Store refrigerated or frozen. Stable for months to years.
- **Reconstituted:** Refrigerate and use within **3–4 weeks** when reconstituted with bacteriostatic water.
- **Avoid:** Repeated freeze-thaw cycles, direct sunlight, and temperatures above 8°C for extended periods.


## BPC-157 Side Effects and Safety Profile

### What the Research Shows

BPC-157 has demonstrated a remarkably favorable safety profile in preclinical studies. Toxicology studies in rodents have found:

- **No lethal dose (LD1) could be established**: even at extremely high doses, no mortality was observed in acute toxicity testing [1]
- **No organ toxicity** was observed at therapeutic or supratherapeutic doses in subchronic studies
- **No mutagenic or carcinogenic effects** have been reported in the existing literature

### Reported Side Effects

In the limited clinical reports and community use, reported side effects are generally mild and infrequent:

- Mild nausea (more common with oral administration)
- Dizziness or lightheadedness (rare)
- Injection site reactions (redness, mild discomfort)
- Headache (infrequent)
- Fatigue or lethargy (rare)

### Important Caveats

Despite the generally favorable safety profile in preclinical work, several important caveats must be noted:

- **Limited human data** — no large-scale human clinical trials exist, so definitive safety claims can't be made
- **Angiogenesis concerns** — blood vessel promotion is a double-edged sword; individuals with active cancer should exercise extreme caution [2]
- **Long-term effects unknown** — most studies examine acute or short-term use only
- **Source quality varies** — contamination and mislabeling are real concerns in the unregulated peptide market
- **Drug interactions possible** — effects on NO, dopaminergic, and other systems suggest potential interactions with medications

> **Important:** Anyone with active malignancies or taking prescription medications should consult a physician before considering BPC-157.


## Is BPC-157 Legal? Current Regulatory Status

### United States (as of 2025–2026)

BPC-157's legal status in the United States has become more restrictive in recent years:

- **FDA classification:** BPC-157 is **not** an FDA-approved drug. It has never completed the FDA approval process for any indication.

- **2022–2024 regulatory actions:** The FDA issued warning letters to several companies marketing BPC-157 for human use, particularly those making therapeutic claims. The FDA's position is that BPC-157 products marketed for human consumption are unapproved new drugs.

- **Compounding pharmacy restrictions:** In late 2023 and into 2024–2025, the FDA moved to restrict compounding pharmacies from producing BPC-157. The FDA placed BPC-157 on its list of substances that cannot be used in compounding under section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, citing insufficient safety and efficacy data and a lack of an established compendial monograph. This significantly reduced access through clinical channels in the US.

- **Research use:** BPC-157 remains available as a research chemical. It can be legally purchased for *in vitro* research and non-human use from research chemical suppliers.

- **Personal use:** The legal situation around personal purchase and use of research peptides exists in a gray area. While purchasing research peptides is not explicitly illegal for individuals, using them for self-administration falls outside FDA-sanctioned use.

### International

- **Canada:** Available through some compounding pharmacies; regulatory framework differs from the US.
- **European Union:** Not approved as a pharmaceutical product. Available in some countries as a research compound.
- **Australia:** Classified under the TGA (Therapeutic Goods Administration). Prescription-level regulation applies. Included on some prohibited substance lists for athletes.
- **WADA (World Anti-Doping Agency):** BPC-157 is **not** currently on the WADA Prohibited List as of 2025, but its status should be verified regularly by competitive athletes, as peptide regulations are subject to change.

> **Note:** Regulatory status can change. Always verify current regulations in your jurisdiction before purchasing or using any peptide.


## Frequently Asked Questions

### Is BPC-157 natural?

Partially. BPC-157 is a *synthetic* peptide, but its amino acid sequence is derived from a naturally occurring protein found in human gastric juice. The specific 15-amino-acid sequence of BPC-157 does not exist as a standalone molecule in the body. It is isolated and synthesized from the larger parent protein for research purposes.

### How quickly does BPC-157 work?

In animal studies, measurable effects on tissue healing have been observed within days, with significant improvements typically documented over 1–4 weeks depending on the injury model. Anecdotal human reports are broadly consistent with this timeline, though individual responses vary.

### Can BPC-157 be taken orally?

Yes. BPC-157 is unusual among peptides in that it demonstrates stability in gastric acid and has shown efficacy via oral administration in animal studies, particularly for gastrointestinal applications [1]. For non-GI targets, subcutaneous injection is more commonly discussed, though some researchers argue systemic effects can be achieved orally.

### Does BPC-157 need to be injected near the injury site?

This is debated. Some protocols recommend local (perilesional) injection near the injured tissue, based on the rationale that local concentration will be higher.

However, animal studies have demonstrated systemic effects even with non-local administration routes, including oral and intraperitoneal [1]. The optimal approach likely depends on the specific application.

### Can BPC-157 be stacked with other peptides?

In the research and clinical communities, BPC-157 is frequently discussed in combination with [TB-500 (Thymosin Beta-4 fragment)](/articles/tb-500-complete-guide) for tissue healing applications. While both peptides promote healing through overlapping but distinct mechanisms, there are no controlled studies examining this combination in humans. The safety and efficacy of combined protocols is not established.

### Is BPC-157 safe for long-term use?

Unknown. The existing safety data is drawn from relatively short-term animal studies. There is no established evidence base for the safety of prolonged human use. The theoretical concern about angiogenesis is particularly relevant in the context of long-term administration.

### Will BPC-157 show up on a drug test?

Standard workplace drug panels do not test for BPC-157. However, advanced peptide-specific testing (as may be used by some sports organizations) could potentially detect it. Athletes subject to testing should consult their sport's governing body.


## What We Still Don't Know About BPC-157

While BPC-157's preclinical evidence base is substantial, with hundreds of published studies, there are important limitations to acknowledge:

1. **Concentration of research:** The majority of BPC-157 studies originate from a single research group (Sikirić et al., University of Zagreb). While their work has been peer-reviewed and published in reputable journals, independent replication by other groups would strengthen the evidence base.

2. **No large human RCTs:** As of early 2026, there are no completed, published, large-scale randomized controlled trials in humans. Some small clinical studies and case reports exist, but the level of evidence remains far below what would be required for pharmaceutical approval.

3. **Dose translation uncertainty:** Extrapolating doses from rodent models to humans using allometric scaling is an imperfect science. Optimal human dosing has not been established through clinical trials.

4. **Long-term safety:** The chronic safety profile in any species is not well characterized.

5. **Mechanism specificity:** While multiple mechanisms have been identified, the relative contribution of each pathway to observed effects, and how these may differ in humans versus rodents, remains unclear.

These gaps do not invalidate the existing research. They simply underscore the need for caution and intellectual honesty when discussing BPC-157's potential.


## Summary

BPC-157 is a synthetic peptide with an extensive preclinical evidence base suggesting benefits for tissue healing, gastrointestinal protection, neuroprotection, and more. Its mechanisms involve angiogenesis, nitric oxide modulation, growth factor upregulation, and interactions with multiple neurotransmitter systems.

The preclinical safety profile is favorable, with no lethal dose established in rodent studies. However, the lack of large-scale human clinical trials means definitive efficacy and safety claims cannot be made for human use.

As of 2025–2026, BPC-157 faces increasing regulatory restrictions in the United States, particularly regarding compounding pharmacy access. It remains available as a research chemical.

For anyone considering BPC-157, consultation with a knowledgeable healthcare provider is strongly recommended.

New to peptides? Start with our [beginner's guide to peptide therapy](/articles/what-are-peptides-beginners-guide). You can also learn about [peptide side effects](/articles/peptide-side-effects-what-to-know) and [how to store peptides properly](/articles/how-to-store-peptides).


## References

1. Sikirić P, Seiwerth S, Ručman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. *Curr Pharm Des.* 2014;20(7):1126-1135. doi:10.2174/13816128113190990411. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23829361/)

2. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. *J Mol Med.* 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27900448/)

3. Tkalčević VI, Čužić S, Brajša K, et al. Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. *Eur J Pharmacol.* 2007;570(1-3):212-221. doi:10.1016/j.ejphar.2007.05.072. [PubMed](https://pubmed.ncbi.nlm.nih.gov/17628536/)

4. Sikirić P, Seiwerth S, Ručman R, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. *Front Pharmacol.* 2018;9:1408. doi:10.3389/fphar.2018.01408.

5. Vukojevic J, Siroglavic M, Kasnik K, et al. Rat inferior caval vein (ICV) ligature and particular pentadecapeptide BPC 157 therapy. *Vasc Pharmacol.* 2018;106:46-57. doi:10.1016/j.vph.2018.02.010. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29501668/)

6. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. *J Appl Physiol.* 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010. [PubMed](https://pubmed.ncbi.nlm.nih.gov/21030672/)

7. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Full and distended stomach, and vascular response. *Inflammopharmacology.* 2006;14(5-6):214-221. doi:10.1007/s10787-006-1531-7. [PubMed](https://pubmed.ncbi.nlm.nih.gov/17091493/)

8. Sikiric P, Rucman R, Turkovic B, et al. Novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157. Vascular recruitment and gastrointestinal tract healing. *Curr Pharm Des.* 2018;24(18):1990-2001. doi:10.2174/1381612824666180515125134. [PubMed](https://pubmed.ncbi.nlm.nih.gov/29756564/)

9. Robert A, Nezamis JE, Lancaster C, Hanchar AJ. Cytoprotection by prostaglandins in rats. Prevention of gastric necrosis produced by alcohol, HCl, NaOH, hypertonic NaCl, and thermal injury. *Gastroenterology.* 1979;77(3):433-443. *Note: foundational cytoprotection reference; BPC-157 cytoprotection data from Sikirić P et al., Life Sci. 1994;54(5):PL63-68.* [PubMed](https://pubmed.ncbi.nlm.nih.gov/8163129/)

Cesarec V, Becejac T, Misic M, et al. Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy.

*Eur J Pharmacol.* 2013;701(1-3):203-212. doi:10.1016/j.ejphar.2012.11.055. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23220707/)

Skorjanec S, Dolovski Z, Kocman I, et al. Therapy for unhealed gastrocutaneous fistulas in rats as a model for analogous healing of persistent skin wounds and persistent gastric ulcers: Stable gastric pentadecapeptide BPC 157.

*Dig Dis Sci.* 2009;54(12):2602-2611. doi:10.1007/s10620-008-0689-x. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19117128/)

Staresinic M, Petrovic I, Novinscak T, et al. Effective therapy of transected quadriceps muscle in rat: Gastric pentadecapeptide BPC 157.

*J Orthop Res.* 2006;24(5):1109-1117. doi:10.1002/jor.20089. [PubMed](https://pubmed.ncbi.nlm.nih.gov/16609979/)

Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat.

*J Orthop Res.* 2010;28(9):1155-1161. doi:10.1002/jor.21107. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20225319/)

Novinscak T, Brcic L, Staresinic M, et al. Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat.

*Surg Today.* 2008;38(8):716-725. doi:10.1007/s00595-007-3706-2. [PubMed](https://pubmed.ncbi.nlm.nih.gov/18668316/)

Sebecic B, Nikolic V, Sikiric P, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation.

*Bone.* 1999;24(3):195-202. doi:10.1016/S8756-3282(98)00180-X. [PubMed](https://pubmed.ncbi.nlm.nih.gov/10071910/)

Tudor M, Jandric I, Marovic A, et al. Traumatic brain injury in mice and pentadecapeptide BPC 157 effect.

*Regul Pept.* 2010;160(1-3):26-32. doi:10.1016/j.regpep.2009.11.012. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19931579/)

Gjurasin M, Miklic P, Zupancic B, et al. Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury.

*Regul Pept.* 2010;160(1-3):33-41. doi:10.1016/j.regpep.2009.11.005. [PubMed](https://pubmed.ncbi.nlm.nih.gov/19903499/)

Barisic I, Balenovic D, Klicek R, et al. Mortal hyperkalemia disturbances in rats are NO-system related.

The life saving effect of pentadecapeptide BPC 157. *Regul Pept.* 2013;181:16-26.

doi:10.1016/j.regpep.2012.12.007. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23318498/)

Ilic S, Brcic I, Mester M, et al. Over-dose insulin and stable gastric pentadecapeptide BPC 157.

Attenuated gastric ulcers, seizures, brain lesions, hepatomegaly, fatty liver, breakdown of liver glycogen, profound hypoglycemia and calcification in rats. *J Physiol Pharmacol.* 2009;60 Suppl 7:107-114. [PubMed](https://pubmed.ncbi.nlm.nih.gov/20388953/)


*Last updated: February 13, 2026*

*This article is maintained by the PeptideRundown Team and updated as new research becomes available. If you find an error or have a suggestion, [contact us](/contact).*

*PeptideRundown.com provides evidence-based educational content about peptides. We do not sell peptides, and we are not affiliated with any peptide supplier. Nothing on this site constitutes medical advice.*
